Bayer Enters a Pivotal Window as Court, Clinic, and Corporate Strategy Converge
14.06.2026 - 11:15:43 | boerse-global.de
Bayer’s stock may be hugging its 200-day moving average, but the company itself is anything but stationary. Over the next few weeks, a trio of high-stakes events — a US Supreme Court ruling, a regulatory green light for a promising stroke drug, and an accelerated push into biofuels — could realign the narrative for the beleaguered German conglomerate. The shares ended the week at €36.06, just a whisker above the 200-day line of €35.99, yet roughly 5% below the 50-day average. On a year-to-date basis, the stock is down about 5%, reflecting the persistent uncertainty that has weighed on Bayer since the Roundup litigation began.
The most anticipated catalyst is the Supreme Court’s decision in the glyphosate case Durnell. Oral arguments were heard in late April, and a verdict is expected by the end of June. If the court rules in Bayer’s favour, the legal foundation for thousands of pending claims would collapse, effectively ending the multibillion-dollar cash drain that has plagued the company. Berenberg analysts assign a 60% probability of a favourable outcome and have raised their price target for the stock to €40.50, while maintaining a “Hold” rating. The financial impact is stark: in the first quarter alone, net cash outflows for settling PCB and glyphosate lawsuits reached €2.002 billion, up from just €66 million in the same period last year. That outflow drove group free cash flow to a negative €2.320 billion.
A separate, yet equally significant, development came on 11 June when the European Medicines Agency validated the marketing application for Asundexian, a novel oral anticoagulant designed to prevent strokes in high-risk patients. The filing is based on the Phase III OCEANIC-STROKE study, which showed a 26% reduction in stroke risk with no increase in major bleeding events. The strong safety profile could make Asundexian a compelling alternative to existing therapies. Approval would give Bayer a valuable new revenue driver in its pharmaceuticals segment, where the pipeline has been under intense scrutiny.
Should investors sell immediately? Or is it worth buying Bayer?
Meanwhile, the company is also reshaping its operations on multiple fronts. On 8 June, Bayer reshuffled the leadership of its Consumer Health division, appointing Analia de la Fuente as global chief data officer, David Tomasi as global chief commercial officer, Samantha Avivi as global chief marketing officer, and Trevor Thrun to lead the US business, the division’s largest market. The overhaul is part of an internal strategy dubbed “Road to Billions”, aimed at accelerating growth and shortening decision-making chains. Dr. Jost Reinhard will also move to lead the radiology unit within pharma starting 1 August.
In the biofuels arena, Bayer is accelerating its North American camelina programme — an oilseed used to produce renewable diesel and sustainable aviation fuel. The original target of reaching one million acres by the mid-2030s has been pulled forward, driven in part by a new partnership with energy giant BP. The company is also lining up contracts with mill operators to give farmers guaranteed offtake, a move designed to de-risk adoption.
Financially, the picture remains mixed. First-quarter group revenue rose to €13.405 billion, while EBITDA before special items climbed 9% to €4.453 billion. Consumer Health posted currency-adjusted sales growth of 5.3% to €1.491 billion, though EBITDA margin slipped slightly to 22.6% on higher marketing costs and currency headwinds. The US market remained soft. CEO Bill Anderson has reaffirmed the full-year outlook: revenue between €44.5 billion and €46.5 billion, and EBITDA before special items between €9.4 billion and €9.9 billion.
With the half-year report due in the coming weeks, investors will soon have a fresh set of numbers to digest. But the real inflection point remains the Supreme Court’s ruling. If it goes Bayer’s way, the shares could finally break free from the legal overhang that has constrained them for years. If it does not, the path forward becomes far murkier. Either way, the next few weeks should provide clarity — and volatility.
Ad
Bayer Stock: New Analysis - 14 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
